| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 1999;30:2752.)
© 1999 American Heart Association, Inc.
Special Report |
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
From UMass/Memorial Health Care, Worcester, Mass.
Correspondence to Marc Fisher, MD, UMass/Memorial Health Care, 119 Belmont St, Worcester, MA 01605. E-mail FisherM{at}ummhc.org
Abstract—The plethora of failed clinical trials with neuroprotective drugs for acute ischemic stroke have raised justifiable concerns about how best to proceed for the future development of such interventions. Preclinical testing of neuroprotective drugs is an important aspect of assessing their therapeutic potential, but guidelines concerning how to perform preclinical development of purported neuroprotective drugs for acute ischemic stroke are lacking. This conference of academicians and industry representatives was convened to suggest such guidelines for the preclinical evaluation of neuroprotective drugs and to recommend to potential clinical investigators the data they should review to reassure themselves that a particular neuroprotective drug has a reasonable chance to succeed in an appropriately designed clinical trial. Without rigorous, robust, and detailed preclinical evaluation, it is unlikely that novel neuroprotective drugs will prove to be effective when tested in large, time-consuming, and expensive clinical trials. Additionally, similar recommendations are provided for drugs with the potential to enhance recovery after acute ischemic stroke, a burgeoning new field with great potential but little currently available data. The suggestions contained in this document are meant to serve as overall guidelines that must be adapted to the individual characteristics related to particular drugs and their preclinical and clinical development needs.
Key Words: neuroprotection • pharmacology • stroke
This article has been cited by other articles:
 |
|
 |
|
  I. Lasarzik, U. Winkelheide, S. C. Thal, N. Benz, M. Lorscher, A. Jahn-Eimermacher, C. Werner, and K. Engelhard Mild Hypothermia Has No Long-Term Impact on Postischemic Neurogenesis in Rats Anesth. Analg., November 1, 2009; 109(5): 1632 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Gibson, B. Coomber, and J. Rathbone Is Progesterone a Candidate Neuroprotective Factor for Treatment following Ischemic Stroke? Neuroscientist, August 1, 2009; 15(4): 324 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 V. E. O'Collins, G. A. Donnan, M. R. Macleod, and D. W. Howells Scope of Preclinical Testing Versus Quality Control Within Experiments Stroke, July 1, 2009; 40(7): e497 - e497. [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, G. Feuerstein, D. W. Howells, P. D. Hurn, T. A. Kent, S. I. Savitz, E. H. Lo, and for the STAIR Group Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations Stroke, June 1, 2009; 40(6): 2244 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Kidwell, K. R. Lees, K. W. Muir, C. Chen, S. M. Davis, D. A. De Silva, C. J. Weir, S. Starkman, J. R. Alger, J. L. Saver, et al. Results of the MRI Substudy of the Intravenous Magnesium Efficacy in Stroke Trial Stroke, May 1, 2009; 40(5): 1704 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dresser First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless. J. Law Med. Ethics, March 1, 2009; 37(1): 38 - 50. [PDF]
|
|
|
|
|
|
M. R. Macleod, M. Fisher, V. O'Collins, E. S. Sena, U. Dirnagl, P. M.W. Bath, A. Buchan, H. B. van der Worp, R. Traystman, K. Minematsu, et al. Good Laboratory Practice: Preventing Introduction of Bias at the Bench Stroke, March 1, 2009; 40(3): e50 - e52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Current Status of Neuroprotection for Cerebral Ischemia: Synoptic Overview Stroke, March 1, 2009; 40(3_suppl_1): S111 - S114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Willing Experimental Models: Help or Hindrance Stroke, March 1, 2009; 40(3_suppl_1): S152 - S154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Simard, V. Yurovsky, N. Tsymbalyuk, L. Melnichenko, S. Ivanova, and V. Gerzanich Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke * Supplemental Methods Stroke, February 1, 2009; 40(2): 604 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Philip, M. Benatar, M. Fisher, and S. I. Savitz Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials Stroke, February 1, 2009; 40(2): 577 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mito, M. Nemoto, H. Kwansa, K. Sampei, M. Habeeb, S. J. Murphy, E. Bucci, and R. C. Koehler Decreased Damage From Transient Focal Cerebral Ischemia by Transfusion of Zero-Link Hemoglobin Polymers in Mouse Stroke, January 1, 2009; 40(1): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Alberts, R. A. Felberg, L. R. Guterman, S. R. Levine, and for Writing Group 4 Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art Circulation, December 16, 2008; 118(25): 2845 - 2851. [Full Text] [PDF]
|
|
|
|
|
|
E. C. Henning, L. L. Latour, J. M. Hallenbeck, and S. Warach Reperfusion-Associated Hemorrhagic Transformation in SHR Rats: Evidence of Symptomatic Parenchymal Hematoma Stroke, December 1, 2008; 39(12): 3405 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Hermann Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 167 - 179. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Macleod, H. B. van der Worp, E. S. Sena, D. W. Howells, U. Dirnagl, and G. A. Donnan Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality Stroke, October 1, 2008; 39(10): 2824 - 2829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Sun, T. A. Doucette, Y. Liu, Y. Fang, L. Teves, M. Aarts, C. L. Ryan, P. B. Bernard, A. Lau, J. P. Forder, et al. Effectiveness of PSD95 Inhibitors in Permanent and Transient Focal Ischemia in the Rat Stroke, September 1, 2008; 39(9): 2544 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-C. Diener, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, A. Shuaib, T. Ashwood, W. Wasiewski, V. Alderfer, et al. NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials Stroke, June 1, 2008; 39(6): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Minnerup, J. Heidrich, J. Wellmann, A. Rogalewski, A. Schneider, and W.-R. Schabitz Meta-Analysis of the Efficacy of Granulocyte-Colony Stimulating Factor in Animal Models of Focal Cerebral Ischemia Stroke, June 1, 2008; 39(6): 1855 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Crossley, E. Sena, J. Goehler, J. Horn, B. van der Worp, P. M.W. Bath, M. Macleod, and U. Dirnagl Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Metaepidemiologic Approach Stroke, March 1, 2008; 39(3): 929 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Gibson, L. J. Gray, P. M. W. Bath, and S. P. Murphy Progesterone for the treatment of experimental brain injury; a systematic review Brain, February 1, 2008; 131(2): 318 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Hussain and A. Shuaib Research Into Neuroprotection Must Continue ... but With a Different Approach Stroke, February 1, 2008; 39(2): 521 - 522. [Full Text] [PDF]
|
|
|
|
|
|
J. Rother Neuroprotection Does Not Work! Stroke, February 1, 2008; 39(2): 523 - 524. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan The 2007 Feinberg Lecture: A New Road Map for Neuroprotection Stroke, January 1, 2008; 39(1): 242 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. van der Worp, E. S. Sena, G. A. Donnan, D. W. Howells, and M. R. Macleod Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis Brain, December 1, 2007; 130(12): 3063 - 3074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Savitz, M. Fisher, P. Lyden, K. R. Lees, and A. Shuaib NXY-059 for the Treatment of Stroke N. Engl. J. Med., November 22, 2007; 357(21): 2198 - 2199. [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, T. Ashwood, and T. Odergren Response to Letter by Proctor and Tamborello Stroke, October 1, 2007; 38(10): e110 - e110. [Full Text] [PDF]
|
|
|
|
|
|
A. Shuaib, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, H.-C. Diener, T. Ashwood, W. W. Wasiewski, U. Emeribe, et al. NXY-059 for the Treatment of Acute Ischemic Stroke N. Engl. J. Med., August 9, 2007; 357(6): 562 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Faden and B. Stoica Neuroprotection: Challenges and Opportunities Arch Neurol, June 1, 2007; 64(6): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Kawaguchi, D. Fukumoto, M. Haida, Y. Ogata, M. Yamano, and H. Tsukada Liposome-Encapsulated Hemoglobin Reduces the Size of Cerebral Infarction in the Rat: Evaluation With Photochemically Induced Thrombosis of the Middle Cerebral Artery Stroke, May 1, 2007; 38(5): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goldberg New Approaches to Clinical Trials in Neuroprotection: Introduction Stroke, February 1, 2007; 38(2): 789 - 790. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Nudo Postinfarct Cortical Plasticity and Behavioral Recovery Stroke, February 1, 2007; 38(2): 840 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, D. F. Hanley, G. Howard, E. C. Jauch, S. Warach, and for the STAIR Group Recommendations From the STAIR V Meeting on Acute Stroke Trials, Technology and Outcomes Stroke, February 1, 2007; 38(2): 245 - 248. [Full Text] [PDF]
|
|
|
|
|
|
Y. Cui, H. Takamatsu, T. Kakiuchi, H. Ohba, Y. Kataoka, C. Yokoyama, H. Onoe, Y. Watanabe, T. Hosoya, M. Suzuki, et al. Neuroprotection by a Central Nervous System-Type Prostacyclin Receptor Ligand Demonstrated in Monkeys Subjected to Middle Cerebral Artery Occlusion and Reperfusion: A Positron Emission Tomography Study Stroke, November 1, 2006; 37(11): 2830 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hackam and D. A. Redelmeier Translation of research evidence from animals to humans. JAMA, October 11, 2006; 296(14): 1731 - 1732. [Full Text] [PDF]
|
|
|
|
|
|
MR Stroke Collaborative Group Proof-of-Principle Phase II MRI Studies in Stroke: Sample Size Estimates From Dichotomous and Continuous Data Stroke, October 1, 2006; 37(10): 2521 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hess NXY-059: A Hopeful Sign in the Treatment of Stroke Stroke, October 1, 2006; 37(10): 2649 - 2650. [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, K. Lees, M. Papadakis, and A. M. Buchan NXY-059: Brain or Vessel Protection Stroke, August 1, 2006; 37(8): 2189 - 2190. [Full Text] [PDF]
|
|
|
|
|
|
C. Iadecola, S. S. Goldman, D. R. Harder, D. D. Heistad, Z. S. Katusic, M. A. Moskowitz, J. M. Simard, M. A. Sloan, R. J. Traystman, and P. A. Velletri Recommendations of the National Heart, Lung, and Blood Institute Working Group on Cerebrovascular Biology and Disease Stroke, June 1, 2006; 37(6): 1578 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Fong and D. H Rhoney NXY-059: Review of Neuroprotective Potential for Acute Stroke Ann. Pharmacother., March 1, 2006; 40(3): 461 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, J. A. Zivin, T. Ashwood, A. Davalos, S. M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, H.-G. Hardemark, et al. NXY-059 for Acute Ischemic Stroke N. Engl. J. Med., February 9, 2006; 354(6): 588 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bright and D. Mochly-Rosen The Role of Protein Kinase C in Cerebral Ischemic and Reperfusion Injury Stroke, December 1, 2005; 36(12): 2781 - 2790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Ho, D. C. Reutens, T. G. Phan, P. M. Wright, R. Markus, I. Indra, D. Young, and G. A. Donnan Is White Matter Involved in Patients Entered into Typical Trials of Neuroprotection? Stroke, December 1, 2005; 36(12): 2742 - 2744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher and T. Tatlisumak Use of Animal Models Has Not Contributed to Development of Acute Stroke Therapies: Con Stroke, October 1, 2005; 36(10): 2324 - 2325. [Full Text] [PDF]
|
|
|
|
|
|
M. Koga, D. C. Reutens, P. Wright, T. Phan, R. Markus, B. Pedreira, G. Fitt, I. Lim, and G. A. Donnan The Existence and Evolution of Diffusion-Perfusion Mismatched Tissue in White and Gray Matter After Acute Stroke Stroke, October 1, 2005; 36(10): 2132 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khanna, S. Roy, A. Slivka, T. K.S. Craft, S. Chaki, C. Rink, M. A. Notestine, A. C. DeVries, N. L. Parinandi, and C. K. Sen Neuroprotective Properties of the Natural Vitamin E {alpha}-Tocotrienol Stroke, October 1, 2005; 36(10): e144 - e152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher and for the Stroke Therapy Academic Industry Roundtabl Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable Stroke, August 1, 2005; 36(8): 1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lutsep Current Status of Hemorrhagic Stroke and Acute Nonthrombolytic Ischemic Stroke Treatment Stroke, November 1, 2004; 35(11_suppl_1): 2746 - 2747. [Full Text] [PDF]
|
|
|
|
|
|
Y. Suzuki, F. Chen, Y. Ni, G. Marchal, D. Collen, and N. Nagai Microplasmin Reduces Ischemic Brain Damage and Improves Neurological Function in a Rat Stroke Model Monitored With MRI Stroke, October 1, 2004; 35(10): 2402 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Barber, L. Hoyte, F. Colbourne, and A. M. Buchan Temperature-Regulated Model of Focal Ischemia in the Mouse: A Study With Histopathological and Behavioral Outcomes Stroke, July 1, 2004; 35(7): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hirt, J. Badaut, J. Thevenet, C. Granziera, L. Regli, F. Maurer, C. Bonny, and J. Bogousslavsky D-JNKI1, a Cell-Penetrating c-Jun-N-Terminal Kinase Inhibitor, Protects Against Cell Death in Severe Cerebral Ischemia Stroke, July 1, 2004; 35(7): 1738 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Macleod, T. O'Collins, D. W. Howells, and G. A. Donnan Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias Stroke, May 1, 2004; 35(5): 1203 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sughrue, E. S. Connolly Jr, M. Krams, K. R. Lees, W. Hacke, A. P. Grieve, J.-M. Orgogozo, and G. A. Ford Effectively Bridging the Preclinical/Clinical Gap: The Results of the ASTIN Trial * Response Stroke, April 1, 2004; 35(4): e81 - e82. [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Danton and W. D. Dietrich The Search for Neuroprotective Strategies in Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 181 - 194. [Full Text] [PDF]
|
|
|
|
|
|
B. Winter, B. Bert, H. Fink, U. Dirnagl, and M. Endres Dysexecutive Syndrome After Mild Cerebral Ischemia?: Mice Learn Normally but Have Deficits in Strategy Switching Stroke, January 1, 2004; 35(1): 191 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Lindner, V. K. Gribkoff, N. A. Donlan, and T. A. Jones Long-Lasting Functional Disabilities in Middle-Aged Rats with Small Cerebral Infarcts J. Neurosci., November 26, 2003; 23(34): 10913 - 10922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gerriets, E. Stolz, M. Walberer, M. Kaps, G. Bachmann, and M. Fisher Neuroprotective Effects of MK-801 in Different Rat Stroke Models for Permanent Middle Cerebral Artery Occlusion: Adverse Effects of Hypothalamic Damage and Strategies for Its Avoidance Stroke, September 1, 2003; 34(9): 2234 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van der Flier, S. P. M. Geelen, J. L. L. Kimpen, I. M. Hoepelman, and E. I. Tuomanen Reprogramming the Host Response in Bacterial Meningitis: How Best To Improve Outcome? Clin. Microbiol. Rev., July 1, 2003; 16(3): 415 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher and T. G. Brott Emerging Therapies for Acute Ischemic Stroke: New Therapies on Trial Stroke, February 1, 2003; 34(2): 359 - 361. [Full Text] [PDF]
|
|
|
|
|
|
K.R. Lees, D. Barer, G.A. Ford, W. Hacke, V. Kostulas, A.K. Sharma, and T. Odergren Tolerability of NXY-059 at Higher Target Concentrations in Patients With Acute Stroke Stroke, February 1, 2003; 34(2): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Caviness, N. Makris, E. Montinaro, N. T. Sahin, J. F. Bates, L. Schwamm, D. Caplan, and D. N. Kennedy Anatomy of Stroke, Part II: Volumetric Characteristics With Implications for the Local Architecture of the Cerebral Perfusion System Stroke, November 1, 2002; 33(11): 2557 - 2564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K W Muir Magnesium in stroke treatment Postgrad. Med. J., November 1, 2002; 78(925): 641 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Furlan Acute Stroke Trials: Strengthening the Underpowered Stroke, June 1, 2002; 33(6): 1450 - 1451. [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir Heterogeneity of Stroke Pathophysiology and Neuroprotective Clinical Trial Design Stroke, June 1, 2002; 33(6): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs: An Opposing View Stroke, January 1, 2002; 33(1): 308 - 309. [Full Text] [PDF]
|
|
|
|
|
|
J. Horn, R.J. de Haan, M. Vermeulen, P.G.M. Luiten, and M. Limburg Nimodipine in Animal Model Experiments of Focal Cerebral Ischemia: A Systematic Review Stroke, October 1, 2001; 32(10): 2433 - 2438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McCulloch and D. Dewar A radical approach to stroke therapy PNAS, September 25, 2001; 98(20): 10989 - 10991. [Full Text] [PDF]
|
|
|
|
|
|
Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies Stroke, July 1, 2001; 32(7): 1598 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Sacco, J. T. DeRosa, E. C. Haley Jr, B. Levin, P. Ordronneau, S. J. Phillips, T. Rundek, R. G. Snipes, J. L. P. Thompson, and for the GAIN Americas Investigators Glycine Antagonist in Neuroprotection for Patients With Acute Stroke: GAIN Americas: A Randomized Controlled Trial JAMA, April 4, 2001; 285(13): 1719 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Samsa and D. B. Matchar Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered? : An Illustration of Three Statistical Principles Stroke, March 1, 2001; 32(3): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. K. Sharma, D. Barer, G. A. Ford, V. Kostulas, Y.-F. Cheng, and T. Odergren Tolerability and Pharmacokinetics of the Nitrone NXY-059 in Patients With Acute Stroke Stroke, March 1, 2001; 32(3): 675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. G. Dyker, A. Sharma, G. A. Ford, M. E. Ardron, and D. G. Grosset Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients : A Dose-Ranging Study Stroke, February 1, 2001; 32(2): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mokudai, I. A. Ayoub, Y. Sakakibara, E-J. Lee, C. S. Ogilvy, K. I. Maynard, and K. Maiese Delayed Treatment With Nicotinamide (Vitamin B3) Improves Neurological Outcome and Reduces Infarct Volume After Transient Focal Cerebral Ischemia in Wistar Rats Editorial Comment Stroke, July 1, 2000; 31(7): 1679 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Furlan CVA: Reducing the Risk of a Confused Vascular Analysis : The Feinberg Lecture Stroke, June 1, 2000; 31(6): 1451 - 1456. [Full Text] [PDF]
|
|